Shining a light on metabolic vulnerabilities in non-small cell lung cancer.

Abstract

Metabolic reprogramming is a hallmark of cancer which contributes to essential processes required for cell survival, growth, and proliferation. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and its genomic classification has given rise to the design of therapies targeting tumors harboring specific gene alterations that cause aberrant signaling. Lung tumors are characterized with having high glucose and lactate use, and high heterogeneity in their metabolic pathways. Here we review how NSCLC cells with distinct mutations reprogram their metabolic pathways and highlight the potential metabolic vulnerabilities that might lead to the development of novel therapeutic strategies.

• Authors: Catríona M Dowling, Hua Zhang, Tríona Ní Chonghaile, Kwok-Kin Wong
• Journal: Biochimica et biophysica acta. Reviews on cancer (Biochim Biophys Acta Rev Cancer) Vol. 1875 Issue 1 Pg. 188462 (01 2021) ISSN: 1879-2561 [Electronic] Netherlands
• PMID: 33130228 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2020. Published by Elsevier B.V.

Topics

• Carcinoma, Non-Small-Cell Lung (genetics, metabolism, pathology)
• Cellular Reprogramming (genetics)
• Humans
• Metabolism (genetics)
• Mutation
• Signal Transduction (genetics)